162 related articles for article (PubMed ID: 34153966)
1. The Use of Neuroprotective Agents in Treating Geographic Atrophy.
Scholl HPN; Boyer D; Giani A; Chong V
Ophthalmic Res; 2021; 64(6):888-902. PubMed ID: 34153966
[TBL] [Abstract][Full Text] [Related]
2. A nonhuman primate model of blue light-induced progressive outer retina degeneration showing brimonidine drug delivery system-mediated cyto- and neuroprotection.
Rajagopalan L; Ghosn C; Tamhane M; Almazan A; Andrews-Jones L; Kulkarni A; Christie LA; Burke J; López FJ; Engles M
Exp Eye Res; 2021 Aug; 209():108678. PubMed ID: 34153289
[TBL] [Abstract][Full Text] [Related]
3. Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Yu HJ; Wykoff CC
BioDrugs; 2021 May; 35(3):303-323. PubMed ID: 33893984
[TBL] [Abstract][Full Text] [Related]
4. Update on geographic atrophy in age-related macular degeneration.
Biarnés M; Monés J; Alonso J; Arias L
Optom Vis Sci; 2011 Jul; 88(7):881-9. PubMed ID: 21532519
[TBL] [Abstract][Full Text] [Related]
5. New Treatment Modalities for Geographic Atrophy.
Kandasamy R; Wickremasinghe S; Guymer R
Asia Pac J Ophthalmol (Phila); 2017; 6(6):508-513. PubMed ID: 28905539
[TBL] [Abstract][Full Text] [Related]
6. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS; Schmidt-Erfurth U; van Lookeren Campagne M; Henry EC; Brittain C
Retina; 2017 May; 37(5):819-835. PubMed ID: 27902638
[TBL] [Abstract][Full Text] [Related]
7. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study.
Liao DS; Metlapally R; Joshi P
Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926
[TBL] [Abstract][Full Text] [Related]
8. Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration.
Pfau M; von der Emde L; de Sisternes L; Hallak JA; Leng T; Schmitz-Valckenberg S; Holz FG; Fleckenstein M; Rubin DL
JAMA Ophthalmol; 2020 Oct; 138(10):1026-1034. PubMed ID: 32789526
[TBL] [Abstract][Full Text] [Related]
9. Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study.
Biarnés M; Arias L; Alonso J; Garcia M; Hijano M; Rodríguez A; Serrano A; Badal J; Muhtaseb H; Verdaguer P; Monés J
Am J Ophthalmol; 2015 Aug; 160(2):345-353.e5. PubMed ID: 25982972
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial.
Brader HS; Ying GS; Martin ER; Maguire MG;
Ophthalmology; 2013 Sep; 120(9):1871-9. PubMed ID: 23622873
[TBL] [Abstract][Full Text] [Related]
11. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
12. New approaches and potential treatments for dry age-related macular degeneration.
Damico FM; Gasparin F; Scolari MR; Pedral LS; Takahashi BS
Arq Bras Oftalmol; 2012; 75(1):71-6. PubMed ID: 22552424
[TBL] [Abstract][Full Text] [Related]
13. Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration: AREDS2 Report 24.
Hwang CK; Agrón E; Domalpally A; Cukras CA; Wong WT; Chew EY; Keenan TDL;
Ophthalmol Retina; 2021 Feb; 5(2):108-117. PubMed ID: 33075546
[TBL] [Abstract][Full Text] [Related]
14. Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.
Vakharia P; Eichenbaum D
Curr Opin Ophthalmol; 2024 May; 35(3):165-169. PubMed ID: 38421937
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Presumptive Inner Nuclear Layer Thickness and Geographic Atrophy Progression in Age-Related Macular Degeneration.
Ebneter A; Jaggi D; Abegg M; Wolf S; Zinkernagel MS
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT299-306. PubMed ID: 27409486
[TBL] [Abstract][Full Text] [Related]
16. Piloting a forced-choice task to elicit treatment preferences in geographic atrophy.
Enoch J; Ghulakhszian A; Sekhon M; Crabb DP; Taylor DJ; Dinah C
BMC Res Notes; 2023 Sep; 16(1):244. PubMed ID: 37777762
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of the complement system in ocular disease.
Rathi S; Hasan R; Ueffing M; Clark SJ
Drug Discov Today; 2023 Nov; 28(11):103757. PubMed ID: 37657753
[TBL] [Abstract][Full Text] [Related]
18. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects.
Danis RP; Lavine JA; Domalpally A
Clin Ophthalmol; 2015; 9():2159-74. PubMed ID: 26640366
[TBL] [Abstract][Full Text] [Related]
19. Incidence and progression of geographic atrophy: observations from a population-based cohort.
Joachim N; Mitchell P; Kifley A; Rochtchina E; Hong T; Wang JJ
Ophthalmology; 2013 Oct; 120(10):2042-50. PubMed ID: 23706948
[TBL] [Abstract][Full Text] [Related]
20. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
